Ventricular Stimulation After Myocardial Infarction

lation (PVS) was a major technique of screening patients at risk for ventricular tachycardia (VT) and VT–related sudden death (1-3). During this time PVS was not considered advantageous for risk stratification in coronary heart disease since implantable cardioverter defibrillators (ICD): a number of landmark trials have shown a benefit of prophylactic ICD implantation in patients with only low left ventricular ejection fraction (LVEF) (4,5). Now, the guidelines recommend the systematic implantation of ICD in patients with history of myocardial infarction (MI) (more than 6 weeks) and LVEF lower than 30% (6). However, proarrhythmic effect of ICD and other complications were reported (7-9). More, inducible VT remains an important and independent factor of cardiac mortality (10).